Journal: Cell reports

Article Title: Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy

doi: 10.1016/j.celrep.2024.114875

Figure Lengend Snippet: (A) UMAP displaying subclustering of select myeloid clusters from CD45 + scRNA-seq and heatmap displaying normalized expression of select genes by monocyte/macrophage cluster. (B) Bar graphs depicting frequency of monocytes/macrophages in each cluster by treatment. (C) Heatmap displaying normalized expression of Mrc1 (CD206), Cx3cr1 , and Nos2 (iNOS) in each monocyte/macrophage cluster by treatment. (D) scRNA-seq dot plot depicting Trem2 and Cx3cr1 expression in combined monocyte/macrophage clusters. (E and F) Representative flow cytometry plots and graphs displaying intratumoral (E) CX3CR1 + CD206 + macrophages or (F) iNOS + macrophages from Y1.7 melanoma-bearing mice treated beginning on day 7 post-tumor transplant and harvested on day 15. For (E) and (F), dot plots displaying CX3CR1 + CD206 + and iNOS + macrophages are gated on macrophages, and bar graphs display the mean ± SEM and are representative of at least three independent experiments (* p < 0.05, ** p < 0.01, **** p < 0.0001; NS, not significant, unpaired t test). See also and .

Article Snippet: Anti-Mouse TREM2 - Fc Muted [clone 178 (LALAPG)] , Leinco Technologies , Cat# T721.

Techniques: Expressing, Flow Cytometry

Journal: Cell reports

Article Title: Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy

doi: 10.1016/j.celrep.2024.114875

Figure Lengend Snippet: (A) Trem2 mRNA detection by quantitative reverse-transcriptase PCR (qRT-PCR) on sorted intratumoral CX3CR1 + CD206 + macrophages and non-CX3CR1 + CD206 + macrophages isolated on day 19 post-tumor transplant from Y1.7LI tumor-bearing mice treated with neoAg SLP vax on days 12 and 18. (B) Schematic depicting the experiment in (C). (C) Tumor growth in mice transplanted with Y1.7LI melanoma cells and receiving intratumoral injections of CX3CR1 + CD206 + macrophages or PBS and treated with control vax, neoAg SLP vax, anti-TREM2, neoAg SLP vax + isotype control mAb (Iso), or neoAg SLP vax + anti-TREM2 as indicated in (B). (D) Tumor growth in Y1.7 melanoma-bearing mice treated with Iso, anti-TREM2, Iso + control vax, Iso + neoAg SLP vax, anti-TREM2 + control vax, or anti-TREM2 + neoAg SLP vax. (E) Schematic depicting experiments in (F)–(H). (F) Graphs displaying frequency of intratumoral CX3CR1 + CD206 + macrophages and iNOS + macrophages. (G) Graph displaying frequency of mLama4 tetramer-positive CD8 T cells. (H) Graph displaying IFN-g + CD8 T cells as assessed by ICS of mLama4 peptide-restimulated CD8 T cells isolated from Y1.7LI tumors. For (A), RNA was isolated from macrophages from two individual mice (two independent experiments). For (C) and (D), fractions indicate number of mice rejecting tumors/number of mice used in the experiment. Scatterplots in (F)–(H) display data for individual mice and are representative of two independent experiments (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; NS, not significant, unpaired t test).

Article Snippet: Anti-Mouse TREM2 - Fc Muted [clone 178 (LALAPG)] , Leinco Technologies , Cat# T721.

Techniques: Reverse Transcription, Quantitative RT-PCR, Isolation, Control

Journal: Cell reports

Article Title: Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy

doi: 10.1016/j.celrep.2024.114875

Figure Lengend Snippet:

Article Snippet: Anti-Mouse TREM2 - Fc Muted [clone 178 (LALAPG)] , Leinco Technologies , Cat# T721.

Techniques: Control, Virus, Recombinant, Lysis, Cloning, Mutagenesis, Sequencing, SYBR Green Assay, Staining, dsDNA Assay, Library Quantification, Software, Real-time Polymerase Chain Reaction